Neue Arzneimittel 2018
U Fricke, L Hein, U Schwabe - Arzneiverordnungs-Report 2019, 2019 - Springer
Bewertung Auf Innovationen entfielen 2018 insgesamt 18 Wirkstoffe mit einem neuartigen
Wirkmechanismus. Besondere Beachtung hat ein gentherapeutisches Arzneimittel …
Wirkmechanismus. Besondere Beachtung hat ein gentherapeutisches Arzneimittel …
Age-and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a population-based self …
M Kang, KN Heo, YM Ah, BR Yang, JY Lee - Maturitas, 2021 - Elsevier
This study aimed to investigate the age-and sex-specific risk of urogenital infections in
patients with type 2 diabetes mellitus (T2DM) treated with sodium-glucose co-transporter 2 …
patients with type 2 diabetes mellitus (T2DM) treated with sodium-glucose co-transporter 2 …
Sodium–glucose linked transporter 2 inhibitor–associated perioperative euglycaemic diabetic ketoacidosis: a case for a perioperative guideline
C Hoffman, M Green, O Megafu - Anaesthesia and Intensive …, 2017 - search.proquest.com
Sodium-glucose linked transporter 2 (SGLT2) is a glucose resorption mediator in the
proximal convoluted tubule in the kidney. Pharmacologic inhibition of this transport protein …
proximal convoluted tubule in the kidney. Pharmacologic inhibition of this transport protein …
[PDF][PDF] Úloha nutričního terapeuta v péči o obézní
A Sadílková, K Čmerdová, A Hásková - Čas Lek česk, 2020 - prolekare.cz
Nastavení správných stravovacích zvyklostí je jedním ze základních pilířů nefarmakologické
léčby obézního pacienta. Nutriční intervence vedená nutričním terapeutem představuje …
léčby obézního pacienta. Nutriční intervence vedená nutričním terapeutem představuje …
Chemical approach to the design of effective antidiabetic agents
AD Rogachev, SO Kuranov… - Russian Chemical …, 2016 - iopscience.iop.org
The review discusses the literature data on the structures of hypoglycemic compounds with
different mechanisms of action. It is shown that many drugs acting on different biological …
different mechanisms of action. It is shown that many drugs acting on different biological …
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
S Niezen, H Diaz del Castillo… - Endocrinology …, 2019 - Wiley Online Library
Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial
burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal …
burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal …
Dapagliflozin/Saxagliptin fixed-dose tablets: a new sodium-glucose cotransporter 2 and dipeptidyl peptidase 4 combination for the treatment of type 2 diabetes
VA Coppenrath, T Hydery - Annals of Pharmacotherapy, 2018 - journals.sagepub.com
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in
therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) …
therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin/saxagliptin) …
[PDF][PDF] Validation of a newly developed stability indicating RP-Liquid Chromatographic Method for the Quantitative Determination of Dapagliflozin
S Sura, RR Modalavalasa, CB Kothapalli - Der Pharma Chemica, 2018 - academia.edu
ABSTRACT A novel simple, user friendly and stability representing high performance liquid
chromatographic method for estimation of dapagliflozin in API and pharmaceutical forms …
chromatographic method for estimation of dapagliflozin in API and pharmaceutical forms …
钠-葡萄糖转运蛋白2 抑制剂达格列净的研究进展
刘宇， 杨佳， 贾德超， 陈烨， 刘程宇， 陈立江 - 辽宁大学学报: 自然科学版, 2015 - cqvip.com
钠-葡萄糖转运蛋白2抑制剂达格列净的研究进展-[维普官方网站]-www.cqvip.com-维普网 我的
维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 …
维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 …
SGLT2 inhibitors-a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology
M Bogowska, A Berner, K Marczyk, K Matyja… - Journal of Education …, 2023 - apcz.umk.pl
Inhibitors of the sodium-glucose cotransporter 2 (SGLT2 inhibitors) are relatively new and
innovative antihyperglycemic drugs which by inhibiting sodium-glucose cotransporter 2 …
innovative antihyperglycemic drugs which by inhibiting sodium-glucose cotransporter 2 …